Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 125 | 2024 | 695 | 15.100 |
Why?
|
Anti-HIV Agents | 38 | 2024 | 154 | 6.840 |
Why?
|
Antiretroviral Therapy, Highly Active | 21 | 2020 | 95 | 3.530 |
Why?
|
Viral Load | 29 | 2024 | 135 | 2.980 |
Why?
|
Humans | 162 | 2024 | 18430 | 2.500 |
Why?
|
Anti-Retroviral Agents | 21 | 2023 | 80 | 2.350 |
Why?
|
Acquired Immunodeficiency Syndrome | 12 | 2023 | 65 | 2.230 |
Why?
|
CD4 Lymphocyte Count | 39 | 2024 | 178 | 2.150 |
Why?
|
Male | 116 | 2024 | 10440 | 2.130 |
Why?
|
Adult | 102 | 2024 | 7910 | 2.030 |
Why?
|
Female | 112 | 2024 | 13136 | 1.950 |
Why?
|
Cohort Studies | 63 | 2024 | 2672 | 1.940 |
Why?
|
Middle Aged | 92 | 2024 | 8284 | 1.900 |
Why?
|
Delivery of Health Care, Integrated | 10 | 2021 | 567 | 1.900 |
Why?
|
Hepatitis C, Chronic | 6 | 2021 | 64 | 1.560 |
Why?
|
Continuity of Patient Care | 7 | 2022 | 112 | 1.460 |
Why?
|
United States | 46 | 2024 | 4164 | 1.370 |
Why?
|
Hepatitis C | 7 | 2022 | 65 | 1.320 |
Why?
|
RNA, Viral | 17 | 2024 | 64 | 1.290 |
Why?
|
Life Expectancy | 4 | 2021 | 33 | 1.270 |
Why?
|
HIV-1 | 15 | 2017 | 71 | 1.270 |
Why?
|
Delivery of Health Care | 7 | 2022 | 444 | 1.270 |
Why?
|
Patient Compliance | 7 | 2015 | 318 | 1.160 |
Why?
|
Retrospective Studies | 28 | 2024 | 2550 | 1.160 |
Why?
|
Neoplasms | 11 | 2024 | 457 | 1.140 |
Why?
|
Electronic Health Records | 9 | 2024 | 747 | 1.130 |
Why?
|
Diabetes Mellitus | 6 | 2024 | 530 | 1.120 |
Why?
|
Quality of Health Care | 2 | 2020 | 347 | 1.030 |
Why?
|
Algorithms | 3 | 2023 | 241 | 0.900 |
Why?
|
Health Services Accessibility | 7 | 2020 | 320 | 0.880 |
Why?
|
Risk Factors | 33 | 2024 | 3449 | 0.860 |
Why?
|
Healthcare Disparities | 5 | 2017 | 211 | 0.820 |
Why?
|
Incidence | 24 | 2024 | 1314 | 0.800 |
Why?
|
Ethnic Groups | 5 | 2021 | 501 | 0.780 |
Why?
|
Treatment Outcome | 13 | 2022 | 1296 | 0.770 |
Why?
|
Aged | 37 | 2024 | 6417 | 0.760 |
Why?
|
Adolescent | 26 | 2022 | 3798 | 0.760 |
Why?
|
Young Adult | 25 | 2022 | 2518 | 0.750 |
Why?
|
Diabetic Foot | 1 | 2020 | 3 | 0.740 |
Why?
|
Continental Population Groups | 2 | 2015 | 315 | 0.740 |
Why?
|
Hepacivirus | 5 | 2022 | 51 | 0.740 |
Why?
|
Raltegravir Potassium | 2 | 2018 | 9 | 0.730 |
Why?
|
Patient Acceptance of Health Care | 4 | 2020 | 407 | 0.680 |
Why?
|
California | 23 | 2020 | 2365 | 0.670 |
Why?
|
District of Columbia | 11 | 2024 | 17 | 0.670 |
Why?
|
Reverse Transcriptase Inhibitors | 4 | 2020 | 21 | 0.670 |
Why?
|
Quality Assurance, Health Care | 2 | 2011 | 188 | 0.670 |
Why?
|
Office Visits | 3 | 2021 | 86 | 0.650 |
Why?
|
Canada | 18 | 2023 | 67 | 0.650 |
Why?
|
Substance Abuse, Intravenous | 3 | 2021 | 32 | 0.640 |
Why?
|
Disease Eradication | 1 | 2018 | 3 | 0.630 |
Why?
|
Appointments and Schedules | 2 | 2021 | 34 | 0.620 |
Why?
|
Comparative Effectiveness Research | 2 | 2019 | 77 | 0.620 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2018 | 110 | 0.610 |
Why?
|
Sexual and Gender Minorities | 3 | 2024 | 27 | 0.600 |
Why?
|
Coinfection | 4 | 2023 | 30 | 0.600 |
Why?
|
Mass Screening | 6 | 2020 | 690 | 0.580 |
Why?
|
Cardiovascular Diseases | 5 | 2022 | 630 | 0.550 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2024 | 180 | 0.540 |
Why?
|
Dyslipidemias | 2 | 2024 | 65 | 0.530 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 26 | 0.530 |
Why?
|
Medication Adherence | 5 | 2020 | 267 | 0.530 |
Why?
|
Low Back Pain | 1 | 2016 | 55 | 0.520 |
Why?
|
Syphilis | 2 | 2020 | 17 | 0.520 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 46 | 0.520 |
Why?
|
HIV | 7 | 2023 | 26 | 0.510 |
Why?
|
Primary Health Care | 8 | 2022 | 848 | 0.490 |
Why?
|
North America | 12 | 2024 | 42 | 0.470 |
Why?
|
Hypertension | 4 | 2024 | 524 | 0.460 |
Why?
|
Viremia | 2 | 2020 | 9 | 0.460 |
Why?
|
End Stage Liver Disease | 3 | 2022 | 11 | 0.450 |
Why?
|
Anemia | 2 | 2024 | 32 | 0.440 |
Why?
|
HIV Seropositivity | 2 | 2017 | 31 | 0.440 |
Why?
|
Cross-Sectional Studies | 14 | 2024 | 1360 | 0.440 |
Why?
|
Prevalence | 11 | 2024 | 911 | 0.440 |
Why?
|
Organophosphorus Compounds | 1 | 2013 | 3 | 0.440 |
Why?
|
Deoxycytidine | 1 | 2013 | 7 | 0.430 |
Why?
|
Insurance Coverage | 4 | 2020 | 136 | 0.430 |
Why?
|
Health Services Research | 1 | 2014 | 264 | 0.430 |
Why?
|
African Continental Ancestry Group | 4 | 2017 | 166 | 0.420 |
Why?
|
Glomerular Filtration Rate | 3 | 2023 | 157 | 0.420 |
Why?
|
Hepatitis B, Chronic | 3 | 2022 | 27 | 0.420 |
Why?
|
Primary Prevention | 1 | 2013 | 79 | 0.410 |
Why?
|
Insurance, Health | 2 | 2020 | 217 | 0.410 |
Why?
|
Socioeconomic Factors | 5 | 2024 | 673 | 0.400 |
Why?
|
Drug Prescriptions | 4 | 2023 | 157 | 0.390 |
Why?
|
Contraception | 1 | 2011 | 25 | 0.390 |
Why?
|
Pregnancy in Diabetics | 1 | 2011 | 21 | 0.390 |
Why?
|
Myocardial Infarction | 3 | 2022 | 249 | 0.390 |
Why?
|
Hepatitis B | 2 | 2023 | 43 | 0.380 |
Why?
|
Antiviral Agents | 4 | 2022 | 95 | 0.380 |
Why?
|
Transgender Persons | 2 | 2022 | 38 | 0.380 |
Why?
|
Sarcoma, Kaposi | 3 | 2021 | 13 | 0.370 |
Why?
|
Diabetes Complications | 1 | 2011 | 119 | 0.370 |
Why?
|
Health Services Administration | 1 | 2010 | 6 | 0.370 |
Why?
|
Fanconi Syndrome | 1 | 2010 | 4 | 0.350 |
Why?
|
Organophosphonates | 1 | 2010 | 7 | 0.350 |
Why?
|
Adenine | 1 | 2010 | 8 | 0.350 |
Why?
|
Tenofovir | 4 | 2023 | 18 | 0.350 |
Why?
|
Proportional Hazards Models | 10 | 2021 | 743 | 0.340 |
Why?
|
HIV Envelope Protein gp41 | 1 | 2009 | 4 | 0.340 |
Why?
|
Pyrrolidinones | 1 | 2009 | 4 | 0.340 |
Why?
|
HIV Protease Inhibitors | 4 | 2020 | 13 | 0.340 |
Why?
|
Peptide Fragments | 1 | 2009 | 28 | 0.340 |
Why?
|
Substance-Related Disorders | 5 | 2021 | 439 | 0.340 |
Why?
|
Gemfibrozil | 1 | 2009 | 5 | 0.330 |
Why?
|
Databases, Factual | 3 | 2023 | 327 | 0.330 |
Why?
|
Oligopeptides | 1 | 2008 | 6 | 0.330 |
Why?
|
Ritonavir | 1 | 2008 | 7 | 0.330 |
Why?
|
Pyridines | 1 | 2008 | 9 | 0.330 |
Why?
|
Hypolipidemic Agents | 1 | 2009 | 44 | 0.330 |
Why?
|
Alcohol Drinking | 3 | 2021 | 375 | 0.320 |
Why?
|
Comorbidity | 8 | 2024 | 619 | 0.320 |
Why?
|
Health Policy | 5 | 2016 | 136 | 0.320 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2022 | 760 | 0.310 |
Why?
|
Models, Theoretical | 2 | 2019 | 76 | 0.310 |
Why?
|
Longitudinal Studies | 6 | 2024 | 724 | 0.310 |
Why?
|
Mental Disorders | 2 | 2022 | 295 | 0.310 |
Why?
|
Logistic Models | 6 | 2014 | 962 | 0.300 |
Why?
|
Aged, 80 and over | 12 | 2019 | 2003 | 0.300 |
Why?
|
Depressive Disorder | 2 | 2019 | 231 | 0.300 |
Why?
|
Serotonin Uptake Inhibitors | 1 | 2008 | 74 | 0.300 |
Why?
|
Community Health Centers | 3 | 2019 | 112 | 0.290 |
Why?
|
Hospitalization | 3 | 2022 | 847 | 0.290 |
Why?
|
Alcoholism | 3 | 2021 | 350 | 0.290 |
Why?
|
Pharmacists | 1 | 2007 | 48 | 0.290 |
Why?
|
Surgical Procedures, Operative | 1 | 2006 | 17 | 0.280 |
Why?
|
Disease Progression | 3 | 2023 | 271 | 0.270 |
Why?
|
Odds Ratio | 5 | 2020 | 701 | 0.270 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 182 | 0.260 |
Why?
|
Drug Resistance, Multiple, Viral | 3 | 2011 | 6 | 0.260 |
Why?
|
Anus Neoplasms | 4 | 2020 | 26 | 0.260 |
Why?
|
Multivariate Analysis | 5 | 2017 | 598 | 0.260 |
Why?
|
Liver Neoplasms | 3 | 2021 | 42 | 0.250 |
Why?
|
Age Distribution | 5 | 2021 | 261 | 0.250 |
Why?
|
Follow-Up Studies | 6 | 2017 | 1269 | 0.250 |
Why?
|
Sexually Transmitted Diseases | 2 | 2022 | 55 | 0.250 |
Why?
|
Erythrocyte Indices | 1 | 2024 | 2 | 0.240 |
Why?
|
Heart Failure | 2 | 2022 | 398 | 0.240 |
Why?
|
Social Stigma | 1 | 2024 | 19 | 0.240 |
Why?
|
Kidney Failure, Chronic | 2 | 2017 | 151 | 0.240 |
Why?
|
Diagnostic Errors | 1 | 2024 | 29 | 0.240 |
Why?
|
Medical Record Linkage | 2 | 2015 | 44 | 0.230 |
Why?
|
Research Design | 4 | 2019 | 402 | 0.230 |
Why?
|
Phenotype | 1 | 2024 | 148 | 0.230 |
Why?
|
Health Status Disparities | 2 | 2019 | 153 | 0.230 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2021 | 26 | 0.230 |
Why?
|
Weight Loss | 3 | 2022 | 321 | 0.220 |
Why?
|
Epidemics | 2 | 2013 | 6 | 0.220 |
Why?
|
Age Factors | 6 | 2020 | 965 | 0.220 |
Why?
|
Fractures, Bone | 1 | 2023 | 91 | 0.210 |
Why?
|
Treatment Failure | 3 | 2012 | 36 | 0.210 |
Why?
|
Polymerase Chain Reaction | 1 | 2022 | 53 | 0.210 |
Why?
|
Lymphoma, AIDS-Related | 3 | 2011 | 18 | 0.210 |
Why?
|
Dementia | 1 | 2024 | 105 | 0.210 |
Why?
|
Homosexuality, Male | 3 | 2024 | 38 | 0.200 |
Why?
|
Life Tables | 1 | 2021 | 11 | 0.200 |
Why?
|
Herpes Zoster | 2 | 2014 | 88 | 0.200 |
Why?
|
Medical Marijuana | 1 | 2022 | 24 | 0.200 |
Why?
|
Severity of Illness Index | 2 | 2021 | 476 | 0.200 |
Why?
|
Mental Health | 2 | 2022 | 168 | 0.200 |
Why?
|
Risk Assessment | 6 | 2024 | 1143 | 0.200 |
Why?
|
Forecasting | 1 | 2022 | 80 | 0.200 |
Why?
|
Mid-Atlantic Region | 3 | 2021 | 9 | 0.200 |
Why?
|
Gastric Bypass | 1 | 2022 | 71 | 0.200 |
Why?
|
Health Care Surveys | 1 | 2022 | 247 | 0.190 |
Why?
|
Health Maintenance Organizations | 3 | 2008 | 479 | 0.190 |
Why?
|
Obesity | 2 | 2019 | 855 | 0.190 |
Why?
|
Infant, Newborn | 2 | 2021 | 872 | 0.190 |
Why?
|
Guideline Adherence | 2 | 2019 | 162 | 0.190 |
Why?
|
Hispanic Americans | 3 | 2021 | 428 | 0.190 |
Why?
|
Amputation | 1 | 2020 | 11 | 0.190 |
Why?
|
Temperature | 1 | 2020 | 18 | 0.190 |
Why?
|
Weight Gain | 2 | 2020 | 181 | 0.180 |
Why?
|
Tobacco Smoking | 1 | 2021 | 20 | 0.180 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2016 | 17 | 0.180 |
Why?
|
Time Factors | 5 | 2016 | 1136 | 0.180 |
Why?
|
Obesity, Morbid | 1 | 2022 | 120 | 0.180 |
Why?
|
Outcome Assessment (Health Care) | 2 | 2016 | 254 | 0.180 |
Why?
|
Smoking | 2 | 2021 | 494 | 0.180 |
Why?
|
Benchmarking | 1 | 2020 | 45 | 0.180 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2020 | 2 | 0.180 |
Why?
|
HIV Integrase Inhibitors | 1 | 2020 | 3 | 0.180 |
Why?
|
Self Report | 1 | 2022 | 256 | 0.180 |
Why?
|
Bariatric Surgery | 1 | 2022 | 130 | 0.180 |
Why?
|
Unsafe Sex | 1 | 2020 | 19 | 0.180 |
Why?
|
Managed Care Programs | 2 | 2021 | 347 | 0.180 |
Why?
|
Gonorrhea | 1 | 2020 | 19 | 0.170 |
Why?
|
Chlamydia Infections | 1 | 2020 | 27 | 0.170 |
Why?
|
Anticoagulants | 1 | 2020 | 125 | 0.170 |
Why?
|
Kidney Transplantation | 2 | 2017 | 29 | 0.170 |
Why?
|
Practice Patterns, Physicians' | 1 | 2023 | 350 | 0.170 |
Why?
|
Lung Neoplasms | 3 | 2021 | 259 | 0.170 |
Why?
|
Anti-Obesity Agents | 1 | 2019 | 18 | 0.170 |
Why?
|
European Continental Ancestry Group | 3 | 2020 | 554 | 0.170 |
Why?
|
Phentermine | 1 | 2019 | 10 | 0.170 |
Why?
|
Health Plan Implementation | 1 | 2019 | 41 | 0.170 |
Why?
|
Appetite Depressants | 1 | 2019 | 16 | 0.170 |
Why?
|
Creatinine | 3 | 2023 | 65 | 0.170 |
Why?
|
Motivational Interviewing | 1 | 2019 | 32 | 0.160 |
Why?
|
Drug Therapy, Combination | 4 | 2021 | 119 | 0.160 |
Why?
|
Text Messaging | 1 | 2019 | 31 | 0.160 |
Why?
|
Smoking Cessation | 1 | 2020 | 199 | 0.160 |
Why?
|
Overweight | 2 | 2019 | 276 | 0.160 |
Why?
|
Blood Glucose | 1 | 2020 | 346 | 0.160 |
Why?
|
Population Surveillance | 3 | 2017 | 271 | 0.160 |
Why?
|
Body Mass Index | 3 | 2019 | 974 | 0.160 |
Why?
|
Disease Notification | 1 | 1998 | 7 | 0.150 |
Why?
|
United States Dept. of Health and Human Services | 2 | 2014 | 7 | 0.150 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2015 | 25 | 0.150 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 168 | 0.150 |
Why?
|
Sex Distribution | 2 | 2015 | 198 | 0.150 |
Why?
|
Referral and Consultation | 2 | 2019 | 180 | 0.150 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 13 | 0.150 |
Why?
|
Living Donors | 1 | 2017 | 3 | 0.150 |
Why?
|
Telemedicine | 1 | 2021 | 184 | 0.150 |
Why?
|
Graft Rejection | 1 | 2017 | 5 | 0.150 |
Why?
|
Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.150 |
Why?
|
Critical Pathways | 1 | 2017 | 11 | 0.150 |
Why?
|
Gastroenterology | 1 | 2017 | 19 | 0.140 |
Why?
|
Societies, Medical | 1 | 2017 | 74 | 0.140 |
Why?
|
Pneumonia | 1 | 2017 | 56 | 0.140 |
Why?
|
HIV Protease | 2 | 2006 | 4 | 0.140 |
Why?
|
Immunocompromised Host | 2 | 2014 | 20 | 0.140 |
Why?
|
Dideoxynucleosides | 1 | 2016 | 8 | 0.140 |
Why?
|
Pneumococcal Infections | 1 | 2016 | 53 | 0.140 |
Why?
|
Geography | 1 | 2016 | 41 | 0.130 |
Why?
|
Regression Analysis | 3 | 2013 | 319 | 0.130 |
Why?
|
Pneumococcal Vaccines | 1 | 2016 | 80 | 0.130 |
Why?
|
Glycated Hemoglobin A | 3 | 2022 | 233 | 0.130 |
Why?
|
African Americans | 4 | 2021 | 490 | 0.130 |
Why?
|
Patient Care | 1 | 2016 | 36 | 0.130 |
Why?
|
Diffusion of Innovation | 1 | 2015 | 44 | 0.130 |
Why?
|
Sex Factors | 4 | 2020 | 661 | 0.130 |
Why?
|
Kidney Function Tests | 2 | 2017 | 22 | 0.120 |
Why?
|
Prospective Studies | 3 | 2022 | 1314 | 0.120 |
Why?
|
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division | 1 | 2014 | 5 | 0.120 |
Why?
|
Risk | 4 | 2021 | 552 | 0.120 |
Why?
|
Neuralgia | 1 | 2014 | 3 | 0.120 |
Why?
|
Safety-net Providers | 1 | 2015 | 63 | 0.120 |
Why?
|
Prostate-Specific Antigen | 1 | 2014 | 77 | 0.120 |
Why?
|
Hepatitis C Antibodies | 1 | 2014 | 3 | 0.120 |
Why?
|
Healthcare Financing | 1 | 2013 | 4 | 0.120 |
Why?
|
Government Programs | 1 | 2013 | 11 | 0.120 |
Why?
|
Internet | 2 | 2013 | 243 | 0.110 |
Why?
|
Quality Indicators, Health Care | 1 | 2015 | 197 | 0.110 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 6 | 0.110 |
Why?
|
Staphylococcal Infections | 1 | 2013 | 15 | 0.110 |
Why?
|
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2013 | 3 | 0.110 |
Why?
|
Protease Inhibitors | 1 | 2012 | 5 | 0.110 |
Why?
|
Breast Neoplasms | 1 | 2021 | 1037 | 0.110 |
Why?
|
Drug Combinations | 1 | 2013 | 43 | 0.110 |
Why?
|
Survival Rate | 1 | 2013 | 269 | 0.110 |
Why?
|
Herpesvirus 3, Human | 1 | 2012 | 49 | 0.100 |
Why?
|
Liver Diseases | 1 | 2012 | 25 | 0.100 |
Why?
|
Drug Resistance, Viral | 2 | 2009 | 13 | 0.100 |
Why?
|
Survival Analysis | 4 | 2016 | 226 | 0.100 |
Why?
|
Biomarkers | 1 | 2013 | 308 | 0.100 |
Why?
|
Aging | 3 | 2022 | 165 | 0.100 |
Why?
|
Bayes Theorem | 2 | 2022 | 69 | 0.100 |
Why?
|
Prostatic Neoplasms | 1 | 2014 | 298 | 0.100 |
Why?
|
Stroke | 1 | 2014 | 311 | 0.100 |
Why?
|
Case-Control Studies | 4 | 2017 | 1173 | 0.100 |
Why?
|
Tuberculosis | 1 | 2011 | 20 | 0.100 |
Why?
|
Urination Disorders | 1 | 2011 | 12 | 0.100 |
Why?
|
Erectile Dysfunction | 1 | 2011 | 25 | 0.100 |
Why?
|
Pandemics | 2 | 2023 | 292 | 0.090 |
Why?
|
Delayed Diagnosis | 1 | 2010 | 19 | 0.090 |
Why?
|
Cooperative Behavior | 3 | 2016 | 102 | 0.090 |
Why?
|
Confidentiality | 2 | 2022 | 30 | 0.090 |
Why?
|
Confounding Factors (Epidemiology) | 2 | 2009 | 99 | 0.090 |
Why?
|
Likelihood Functions | 1 | 2010 | 48 | 0.090 |
Why?
|
Appendicitis | 1 | 2009 | 16 | 0.090 |
Why?
|
Hemoglobins | 2 | 2024 | 39 | 0.090 |
Why?
|
Mutation | 2 | 2011 | 132 | 0.080 |
Why?
|
Pregnancy Complications | 1 | 2011 | 193 | 0.080 |
Why?
|
Atazanavir Sulfate | 1 | 2008 | 5 | 0.080 |
Why?
|
Triglycerides | 1 | 2009 | 87 | 0.080 |
Why?
|
Sustained Virologic Response | 2 | 2019 | 17 | 0.080 |
Why?
|
Mortality | 1 | 2009 | 123 | 0.080 |
Why?
|
Interrupted Time Series Analysis | 2 | 2021 | 24 | 0.080 |
Why?
|
Pregnancy | 2 | 2011 | 1516 | 0.080 |
Why?
|
History, 21st Century | 2 | 2019 | 25 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2015 | 656 | 0.080 |
Why?
|
Cholesterol, LDL | 1 | 2009 | 125 | 0.080 |
Why?
|
Predictive Value of Tests | 3 | 2017 | 365 | 0.080 |
Why?
|
AIDS Serodiagnosis | 1 | 2007 | 10 | 0.080 |
Why?
|
Recurrence | 2 | 2022 | 187 | 0.080 |
Why?
|
Health Promotion | 1 | 2011 | 294 | 0.080 |
Why?
|
Prognosis | 3 | 2017 | 624 | 0.070 |
Why?
|
Program Evaluation | 2 | 2020 | 244 | 0.070 |
Why?
|
Medical Indigency | 1 | 2006 | 5 | 0.070 |
Why?
|
Early Detection of Cancer | 3 | 2021 | 526 | 0.070 |
Why?
|
Drug Information Services | 1 | 2005 | 3 | 0.070 |
Why?
|
Medication Errors | 1 | 2005 | 7 | 0.070 |
Why?
|
Drug Utilization Review | 1 | 2005 | 26 | 0.060 |
Why?
|
Quality Improvement | 2 | 2020 | 207 | 0.060 |
Why?
|
Registries | 3 | 2013 | 490 | 0.060 |
Why?
|
Infant | 2 | 2022 | 1245 | 0.060 |
Why?
|
Drug Administration Schedule | 3 | 2013 | 100 | 0.060 |
Why?
|
Medical Records Systems, Computerized | 1 | 2005 | 95 | 0.060 |
Why?
|
Evidence-Based Practice | 2 | 2015 | 56 | 0.060 |
Why?
|
Genotype | 3 | 2011 | 253 | 0.060 |
Why?
|
Multimorbidity | 1 | 2024 | 14 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 131 | 0.060 |
Why?
|
DNA, Viral | 1 | 2023 | 17 | 0.060 |
Why?
|
Hepatitis B virus | 1 | 2023 | 21 | 0.060 |
Why?
|
Eligibility Determination | 1 | 2022 | 17 | 0.050 |
Why?
|
RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
Patient Participation | 2 | 2015 | 144 | 0.050 |
Why?
|
Kidney | 1 | 2023 | 54 | 0.050 |
Why?
|
Gastrectomy | 1 | 2022 | 46 | 0.050 |
Why?
|
Gender Identity | 1 | 2022 | 36 | 0.050 |
Why?
|
Anxiety Disorders | 1 | 2022 | 93 | 0.050 |
Why?
|
Documentation | 1 | 2022 | 45 | 0.050 |
Why?
|
Prescriptions | 1 | 2022 | 28 | 0.050 |
Why?
|
Sexual Behavior | 1 | 2022 | 123 | 0.050 |
Why?
|
Administration, Oral | 1 | 2020 | 86 | 0.050 |
Why?
|
Oxazines | 1 | 2020 | 2 | 0.050 |
Why?
|
Condoms | 1 | 2020 | 32 | 0.040 |
Why?
|
Piperazines | 1 | 2020 | 9 | 0.040 |
Why?
|
Pyridones | 1 | 2020 | 8 | 0.040 |
Why?
|
Immunosuppression | 1 | 2020 | 9 | 0.040 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 51 | 0.040 |
Why?
|
Sexual Partners | 1 | 2020 | 37 | 0.040 |
Why?
|
Pilot Projects | 1 | 2021 | 237 | 0.040 |
Why?
|
Epidemiologic Methods | 2 | 2010 | 87 | 0.040 |
Why?
|
Mood Disorders | 1 | 2019 | 19 | 0.040 |
Why?
|
Esophageal and Gastric Varices | 1 | 2019 | 4 | 0.040 |
Why?
|
Washington | 1 | 2020 | 388 | 0.040 |
Why?
|
Liver | 1 | 2019 | 33 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 133 | 0.040 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2019 | 20 | 0.040 |
Why?
|
Liver Cirrhosis | 1 | 2019 | 34 | 0.040 |
Why?
|
Insulin | 1 | 2020 | 208 | 0.040 |
Why?
|
Blood Pressure | 1 | 2021 | 310 | 0.040 |
Why?
|
Minority Groups | 1 | 2019 | 105 | 0.040 |
Why?
|
Prediabetic State | 1 | 2019 | 53 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2019 | 399 | 0.040 |
Why?
|
Depressive Disorder, Major | 1 | 2019 | 127 | 0.040 |
Why?
|
Molecular Sequence Data | 2 | 2009 | 18 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 270 | 0.040 |
Why?
|
Anxiety | 1 | 2019 | 156 | 0.040 |
Why?
|
Communication | 1 | 2020 | 202 | 0.040 |
Why?
|
Prejudice | 1 | 1998 | 24 | 0.040 |
Why?
|
Behavior Therapy | 1 | 2019 | 155 | 0.040 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 288 | 0.040 |
Why?
|
Graft Survival | 1 | 2017 | 3 | 0.040 |
Why?
|
Nephrectomy | 1 | 2017 | 6 | 0.040 |
Why?
|
Chronic Disease | 1 | 2020 | 468 | 0.040 |
Why?
|
Child | 2 | 2015 | 2571 | 0.040 |
Why?
|
Patient Outcome Assessment | 1 | 2017 | 29 | 0.040 |
Why?
|
Serogroup | 1 | 2016 | 10 | 0.040 |
Why?
|
Streptococcus pneumoniae | 1 | 2016 | 25 | 0.040 |
Why?
|
Vaccines, Conjugate | 1 | 2016 | 66 | 0.030 |
Why?
|
United States Department of Veterans Affairs | 1 | 2017 | 126 | 0.030 |
Why?
|
Surveys and Questionnaires | 2 | 2011 | 1389 | 0.030 |
Why?
|
Decision Support Techniques | 1 | 2017 | 95 | 0.030 |
Why?
|
Patient Care Team | 1 | 2017 | 127 | 0.030 |
Why?
|
Health Surveys | 1 | 2017 | 269 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 114 | 0.030 |
Why?
|
Inservice Training | 1 | 2015 | 15 | 0.030 |
Why?
|
Demography | 1 | 2016 | 108 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2015 | 63 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2016 | 253 | 0.030 |
Why?
|
Reminder Systems | 1 | 2015 | 94 | 0.030 |
Why?
|
Depression | 1 | 2019 | 518 | 0.030 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2013 | 1 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 333 | 0.030 |
Why?
|
Platelet Count | 1 | 2013 | 9 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2013 | 14 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2013 | 45 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2013 | 22 | 0.030 |
Why?
|
Hematologic Neoplasms | 1 | 2012 | 8 | 0.030 |
Why?
|
Reference Values | 1 | 2012 | 93 | 0.030 |
Why?
|
SEER Program | 1 | 2012 | 101 | 0.030 |
Why?
|
Virus Replication | 1 | 2011 | 12 | 0.030 |
Why?
|
Vaccination | 1 | 2016 | 674 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2013 | 226 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2011 | 9 | 0.020 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2011 | 4 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 51 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 1 | 2011 | 11 | 0.020 |
Why?
|
Psychometrics | 1 | 2011 | 124 | 0.020 |
Why?
|
Immunization Programs | 1 | 2011 | 68 | 0.020 |
Why?
|
Child, Preschool | 1 | 2015 | 1478 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 83 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2009 | 55 | 0.020 |
Why?
|
Models, Statistical | 1 | 2009 | 185 | 0.020 |
Why?
|
Financing, Government | 1 | 2007 | 32 | 0.020 |
Why?
|
Influenza Vaccines | 1 | 2011 | 290 | 0.020 |
Why?
|
Quality of Life | 1 | 2011 | 529 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2006 | 2 | 0.020 |
Why?
|
Base Sequence | 1 | 2006 | 20 | 0.020 |
Why?
|
Nelfinavir | 1 | 2006 | 4 | 0.020 |
Why?
|
Phylogeny | 1 | 2006 | 14 | 0.020 |
Why?
|
Research | 1 | 2007 | 73 | 0.020 |
Why?
|
Medicare | 1 | 2007 | 214 | 0.020 |
Why?
|
Medicaid | 1 | 2007 | 211 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2007 | 142 | 0.020 |
Why?
|
Drug Interactions | 1 | 2005 | 20 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2005 | 78 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2005 | 214 | 0.010 |
Why?
|